المؤلفون: Haj Mohammad SF; Department of Medical Oncology, Leiden University Medical Center, Leiden, the Netherlands; Department of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands. s.f.haj_mohammad@lumc.nl., Timmer HJL; Department of Medical Oncology, Leiden University Medical Center, Leiden, the Netherlands; Department of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands., Zeverijn LJ; Department of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands., Geurts BS; Department of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands., Spiekman IAC; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands., Verkerk K; Department of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands., Verbeek FAJ; Department of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands., Verheul HMW; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands., Voest EE; Department of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands., Gelderblom H; Department of Medical Oncology, Leiden University Medical Center, Leiden, the Netherlands.

المصدر: Acta oncologica (Stockholm, Sweden) [Acta Oncol] 2024 May 23; Vol. 63, pp. 368-372. Date of Electronic Publication: 2024 May 23.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Medical Journals Sweden AB Country of Publication: Sweden NLM ID: 8709065 Publication Model: Electronic Cited Medium: Internet ISSN: 1651-226X (Electronic) Linking ISSN: 0284186X NLM ISO Abbreviation: Acta Oncol Subsets: MEDLINE

مواضيع طبية MeSH: Neoplasms*/drug therapy , Neoplasms*/genetics , Precision Medicine*/methods, Humans ; Netherlands ; Immunotherapy/methods ; Medical Oncology/methods ; Medical Oncology/trends ; Piperazines/therapeutic use ; Pyridines/therapeutic use ; Nivolumab/therapeutic use ; Antineoplastic Agents/therapeutic use ; Molecular Targeted Therapy/methods

المؤلفون: Spiekman IAC; Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus MC, Rotterdam, The Netherlands., Geurts BS; Oncode Institute, Utrecht, The Netherlands.; Department of Molecular Oncology and Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Zeverijn LJ; Oncode Institute, Utrecht, The Netherlands.; Department of Molecular Oncology and Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., de Wit GF; Oncode Institute, Utrecht, The Netherlands.; Department of Molecular Oncology and Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., van der Noort V; Department of Biometrics, Netherlands Cancer Institute, Amsterdam, The Netherlands., Roepman P; Hartwig Medical Foundation, Amsterdam, The Netherlands., de Leng WWJ; Department of Pathology, University Medical Cancer Center Utrecht, Utrecht, The Netherlands., Jansen AML; Department of Pathology, University Medical Cancer Center Utrecht, Utrecht, The Netherlands., Kusters B; Department of Pathology, Radboud University Medical Center, Nijmegen, The Netherlands., Beerepoot LV; Department of Internal Medicine, ETZ Hospital (Elisabeth-TweeSteden Ziekenhuis), Tilburg, The Netherlands., de Vos FYFL; Department of Medical Oncology, University Medical Center Utrecht, Utrecht, The Netherlands., de Groot DA; Department of Medical Oncology, University Medical Center Groningen, Groningen, The Netherlands., de Groot JWB; Isala Oncology Center, Isala, Zwolle, The Netherlands., Hoeben A; Division of Medical Oncology, Department of Internal Medicine, GROW School of Oncology and Development Biology, Maastricht University Center+, Maastricht, The Netherlands., Buter J; Department of Medical Oncology, Amsterdam University Medical Center, Location VuMC, Amsterdam, The Netherlands., Gelderblom HAJ; Department of Medical Oncology, Leiden University Medical Center, Leiden, The Netherlands., Voest EE; Oncode Institute, Utrecht, The Netherlands.; Department of Molecular Oncology and Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.; Center for Personalized Cancer Treatment, Rotterdam,The Netherlands., Verheul HMW; Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus MC, Rotterdam, The Netherlands.

المصدر: The oncologist [Oncologist] 2024 May 03; Vol. 29 (5), pp. 431-440.

نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Oxford University Press Country of Publication: England NLM ID: 9607837 Publication Model: Print Cited Medium: Internet ISSN: 1549-490X (Electronic) Linking ISSN: 10837159 NLM ISO Abbreviation: Oncologist Subsets: MEDLINE

مواضيع طبية MeSH: Panitumumab*/therapeutic use , Panitumumab*/adverse effects , Panitumumab*/pharmacology , Glioblastoma*/drug therapy , Glioblastoma*/genetics , Glioblastoma*/pathology , Glioblastoma*/mortality, Humans ; Female ; Male ; Middle Aged ; Aged ; Adult ; Brain Neoplasms/drug therapy ; Brain Neoplasms/genetics ; Antineoplastic Agents, Immunological/therapeutic use ; Antineoplastic Agents, Immunological/adverse effects ; ras Proteins/genetics ; raf Kinases/genetics ; raf Kinases/antagonists & inhibitors

المؤلفون: Spiekman IAC; Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus MC, Rotterdam, the Netherlands., Zeverijn LJ; Oncode Institute, Utrecht, the Netherlands; Department of Molecular Oncology & Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Geurts BS; Oncode Institute, Utrecht, the Netherlands; Department of Molecular Oncology & Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Verkerk K; Oncode Institute, Utrecht, the Netherlands; Department of Molecular Oncology & Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Haj Mohammad SF; Department of Molecular Oncology & Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands; Department of Medical Oncology, Leiden University Medical Center, Leiden, the Netherlands., van der Noort V; Department of Biometrics, Netherlands Cancer Institute, Amsterdam, the Netherlands., Roepman P; Hartwig Medical Foundation, Amsterdam, the Netherlands., de Leng WWJ; Department of Pathology, University Medical Center Utrecht, Utrecht, the Netherlands., Jansen AML; Department of Pathology, University Medical Center Utrecht, Utrecht, the Netherlands., Gootjes EC; Department of Medical Oncology, Radboud University Medical Center, Nijmegen, the Netherlands., de Groot DA; Department of Medical Oncology, University Medical Center Groningen, Groningen, the Netherlands., Kerver ED; Department of Medical Oncology, OLVG, Amsterdam, the Netherlands., van Voorthuizen T; Department of Medical Oncology, Rijnstate, Arnhem, the Netherlands., Roodhart JML; Department of Medical Oncology, University Medical Center Utrecht, Utrecht, the Netherlands., Valkenburg-van Iersel LBJ; Division of Medical Oncology, Department of Internal Medicine, GROW school of Oncology and Development Biology, Maastricht University Center+, Maastricht, the Netherlands., Gelderblom H; Department of Medical Oncology, Leiden University Medical Center, Leiden, the Netherlands., Voest EE; Oncode Institute, Utrecht, the Netherlands; Department of Molecular Oncology & Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Verheul HMW; Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus MC, Rotterdam, the Netherlands. Electronic address: h.verheul@erasmusmc.nl.

المصدر: European journal of cancer (Oxford, England : 1990) [Eur J Cancer] 2024 May; Vol. 202, pp. 113988. Date of Electronic Publication: 2024 Mar 07.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Elsevier Science Ltd Country of Publication: England NLM ID: 9005373 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-0852 (Electronic) Linking ISSN: 09598049 NLM ISO Abbreviation: Eur J Cancer Subsets: MEDLINE

مواضيع طبية MeSH: Antibodies, Monoclonal, Humanized* , Colorectal Neoplasms*/drug therapy , Colorectal Neoplasms*/genetics , Receptor, ErbB-2*/genetics, Humans ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Proto-Oncogene Proteins B-raf/genetics ; Trastuzumab/adverse effects ; Trastuzumab/therapeutic use